Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference
18 juin 2019 08h27 HE
|
Aptinyx Inc.
EVANSTON, Ill., June 18, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Appoints Henry Gosebruch to Its Board of Directors
07 mai 2019 07h23 HE
|
Aptinyx Inc.
EVANSTON, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers
30 avr. 2019 07h27 HE
|
Aptinyx Inc.
Favorable overall safety, tolerability, and pharmacokinetic profile—no serious adverse events reported across wide dose range Achieved ample CNS exposure consistent with exposure observed at...
Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update
29 avr. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Major Depressive Disorder
07 janv. 2019 06h00 HE
|
Axsome Therapeutics, Inc.
Demonstrated statistically significant improvement in MADRS scores compared to active comparator (p<0.001 on primary endpoint) Rapid improvement in depressive symptoms demonstrating statistically...
Otonomy Announces Phase 3 Clinical Trial Plan for OTIPRIO™ in Otitis Externa Patients Based on Successful End-of-Phase 2 Review by FDA
18 avr. 2016 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a Treatment for Tinnitus
06 nov. 2014 01h00 HE
|
Otonomy, Inc.
SAN DIEGO and PARIS, Nov. 6, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative...